Acute nonlymphocytic leukemia after transient myeloproliferative disorder in a patient with down syndrome

Barnett, Peter; Clark, Angela; Garson, O. Margaret

doi:10.1002/mpo.2950180502

Cited by 19 publications

(11 citation statements)

References 34 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An acquired chromosome 21 (i.e. tetrasomy 21) t(21;21) and i21 are most common ( Barnett et al , 1990 ).…”

Section: Transient Myeloproliferative Disordermentioning

confidence: 99%

“…If leukaemia develops following TMD, it is almost always AMKL and it usually occurs between the ages of 1 and 3 years ( Lin et al , 1980 ; Nito et al , 1983 ; Ruiz‐Argielles et al , 1986 ; Barnett et al , 1990 ; Zipursky et al , 1992 ). That both TMD and AML are usually phenotypically AMKL suggests that the second disease is derived from the first.…”

Section: Transient Myeloproliferative Disordermentioning

confidence: 99%

See 1 more Smart Citation

The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome

2000

View full text Add to dashboard Cite

“…An acquired chromosome 21 (i.e. tetrasomy 21) t(21;21) and i21 are most common ( Barnett et al , 1990 ).…”

Section: Transient Myeloproliferative Disordermentioning

confidence: 99%

Section: Transient Myeloproliferative Disordermentioning

confidence: 99%

The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome

2000

View full text Add to dashboard Cite

“…Unlike TL, if left untreated, the subsequent leukemia does not spontaneously regress. 4,5,15,[17][18][19] In 1996, the Pediatric Oncology Group (POG) initiated the first prospective study (POG 9481) to look at the clinical features, biology, and natural history of TL in children with DS (or trisomy 21 mosaicism), and to identify DS infants at risk for early death or development of subsequent leukemia.…”

Section: Introductionmentioning

confidence: 99%

A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481

Massey

Zipursky

Chang

et al. 2006

Blood

278

342

View full text Add to dashboard Cite

A unique transient leukemia (TL) has been described in newborns with Down syndrome (DS; or trisomy 21 mosaics). This leukemia has a high incidence of spontaneous remission; however, early death and subsequent development of acute megakaryoblastic leukemia (AMKL) have been reported. We prospectively evaluated 48 infants with DS and TL to determine the natural history and biologic characteristics of this disease, identify the clinical characteristics associated with early death or subsequent leukemia, and assess the incidence of subsequent leukemia. Blast cells associated with TL in DS infants exhibited FAB M 7 morphology and phenotype. Most infants (74%) had trisomy 21 (or mosaicism) as the only cytogenetic abnormality in the blast cells. Most children were able to spontaneously clear peripheral blasts (89%), normalize blood counts (74%), and maintain a complete remission (64%). Early death occurred in 17% of infants and was significantly correlated with higher white blood cell count at diagnosis (P < .001), increased bilirubin and liver enzymes (P < .005), and a failure to normalize the blood count (P ‫؍‬ .001). Recurrence of leukemia occurred in 19% of infants at a mean of 20 months. Development of leukemia was significantly correlated with karyotypic abnormalities in addition to trisomy 21 (P ‫؍‬ .037). Ongoing collaborative clinical studies are needed to determine the optimal role of chemotherapy for infants at risk for increased mortality or disease recurrence and to further the knowledge of the unique biologic features of this TL. (Blood. 2006; 107:4606-4613)

show abstract

“…Most of the information about the natural history and biology of this TL has been gleaned from sporadic case reports and/or retrospective reviews of medical and/or pathologic records 4,5,15,17. Although the disease may spontaneously disappear, a significant percentage of patients with TL go on to develop AMKL within the first 4 years of life, which if left untreated rarely shows spontaneous regression a second time 4,5,15,17–19. The Pediatric Oncology Group Study 9481 was the first study designed to prospectively study the clinical presentation and natural history of DS children (or trisomy 21 mosaics) with TL, to determine the immunophenotypic, cytogenetic, and clonal characteristics of the blast cells in this disorder, and to assess their prognostic significance for the development of acute non‐lymphocytic leukemia.…”

Section: Clinical Characteristics At Presentation Of Patients With Trmentioning

confidence: 99%

Investigation of mechanism of Al(OH)₃ crystal growth

2009

View full text Add to dashboard Cite

Crystallization of Al(OH) 3 that occurs during the decomposition of caustic soda solutions is an important part of Bayer process for alumina production. Several phenomena, which influence the physicochemical characteristics of precipitated Al(OH) 3 , occur simultaneously during this process. They are nucleation, agglomeration, and crystal growth of Al(OH) 3 . In this article, we have investigated the mechanism of Al(OH) 3 crystal growth from pure caustic soda solutions and in the presence of oxalic acid.The results have shown that the growth of Al(OH) 3 crystals from caustic soda solutions follow the B + S model (birth and spread). New Al(OH) 3 particles, formed during the decomposition process of pure caustic soda solutions, are characterized by regular hexagonal shape. The nuclei have the same geometry as the contact face. However, microstructural investigations of Al(OH) 3 samples, obtained by crystallization from caustic soda solutions in the presence of oxalic acid, have shown the presence of nuclei of irregular shape in addition to regular ones. So, the presence of oxalic acid in the caustic soda solutions leads to a change in crystal habit.Besides, the results obtained by kinetic investigation confirmed the mentioned mechanism of Al(OH) 3 crystal growth.La cristallisation de l'Al(OH) 3 qui accompagne la décomposition de solutions de soude caustique est une caractéristique importante du procédé Bayer de production d'alumine. Plusieurs phénomènes influant sur les caractéristiques physicochimiques de l'Al(OH) 3 précipité, se produisent simultanément lors de ce procédé. Ce sont la nucléation, l'agglomération et la croissance des cristaux de l'Al(OH) 3 . Dans cet article, nous avonsétudié le mécanisme de croissance des cristaux de l'Al(OH) 3à partir de solutions de soude caustique pures et en présence d'acide oxalique. Les résultats montrent que la croissance des cristaux d'Al(OH) 3à partir des solutions de soude caustique suit le modèle B + S (naissance (birth) + dispersion (spread)). Les nouvelles particules d'Al(OH) 3 , formées lors du procédé de décomposition des solutions de soude caustique, se caractérisent par une forme hexagonale régulière. Les nuclei ont la même géométrie que la face de contact. Cependant, des recherches sur la microstructure deséchantillons d'Al(OH) 3 obtenus par cristallisationà partir des solutions de soude caustique en présence d'acide oxalique, montrent la présence de nuclei de forme irrégulière en plus de ceux de forme régulière. Ainsi, la présence d'acide oxalique dans les solutions de soude caustique mèneà un changement dans le comportement des cristaux. En outre, les résultats obtenus dans l'étude cinétique confirment ce mécanisme de croissance des cristaux d'Al(OH) 3 .

show abstract

Acute nonlymphocytic leukemia after transient myeloproliferative disorder in a patient with down syndrome

Cited by 19 publications

References 34 publications

The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome

The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome

A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481

Investigation of mechanism of Al(OH)₃ crystal growth

Contact Info

Product

Resources

About

Acute nonlymphocytic leukemia after transient myeloproliferative disorder in a patient with down syndrome

Cited by 19 publications

References 34 publications

The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome

The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome

A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481

Investigation of mechanism of Al(OH)3 crystal growth

Contact Info

Product

Resources

About

Investigation of mechanism of Al(OH)₃ crystal growth